Riverhead Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Riverhead Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$115K	Hold	1,583	–	–	﹤0.01%	1296
2019 Q2	$130K	Hold	1,583	–	–	﹤0.01%	1278
2019 Q1	$112K	Hold	1,583	–	–	﹤0.01%	1306
2018 Q4	$71K	Hold	1,583	–	–	﹤0.01%	1371
2018 Q3	$89K	Buy	1,583 +400	+34%	+$24.5K	﹤0.01%	1416
2018 Q2	$79K	Hold	1,183	–	–	﹤0.01%	1399
2018 Q1	$69K	Hold	1,183	–	–	﹤0.01%	1418
2017 Q4	$76K	Buy	1,183 +100	+9%	+$6.22K	﹤0.01%	1411
2017 Q3	$57K	Buy	1,083 +185	+21%	+$8.82K	﹤0.01%	1422
2017 Q2	$42K	Buy	898 +498	+125%	+$24K	﹤0.01%	1453
2017 Q1	$20K	Buy	+400	New	+$22.5K	﹤0.01%	1466

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Riverhead Capital Management's ANIP Position: Q3 2019 in Review

Riverhead Capital Management held its ANI Pharmaceuticals (ANIP) position steady in Q3 2019 at 1,583 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Riverhead Capital Management first reported a position in ANIP in Q1 2017 and has held it in 11 quarters since. The position peaked at $130K in Q2 2019. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Riverhead Capital Management held 1,583 shares of ANI Pharmaceuticals worth $115K as of Q3 2019.
Riverhead Capital Management left its ANI Pharmaceuticals share count unchanged in Q3 2019.
ANI Pharmaceuticals made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1296 holding.
Riverhead Capital Management first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
Riverhead Capital Management's ANI Pharmaceuticals position peaked at $130K in Q2 2019.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.